HighTide Therapeutics
Manufacturing · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11140 Rockville Pike Ste 100-551, Rockvi...Phone Number
+61 414668863Website
www.hightidetx.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About HighTide Therapeutics
HighTide Therapeutics, Inc. is focused on developing innovative therapeutic solutions for chronic metabolic diseases, particularly those related to cardiovascular-kidney-metabolic (CKM) conditions. Their lead candidate, HTD1801, targets diseases driven by insulin resistance and chronic inflammation. The company also has a growing discovery portfolio aimed at addressing unmet needs in this area. HighTide Therapeutics is dedicated to advancing treatments that improve patient outcomes in chronic metabolic diseases.Explore more
HighTide Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HighTide Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when HighTide Therapeutics launches new products
Click to see if HighTide Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once HighTide Therapeutics has new funding data
Check out if HighTide Therapeutics is spiking on competitors!
Check if HighTide Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on HighTide Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at HighTide Therapeutics
HighTide Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to HighTide Therapeutics
Compare insights from companies similar to HighTide Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HighTide Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HighTide Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HighTide Therapeutics.
HighTide Therapeutics financials insights
Gather financial insights about HighTide Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$60M
2023
Series C
$107M
HighTide Therapeutics Tech Stack
A closer look at the technologies used by HighTide Therapeutics
See more technologies
Most Recent Scoops
Event
Events
Funding
New Hire
Management Move
Daniel Ripley has joined the company as Senior VP, Business Development. Previously, Ripley was Head of Global Business Development for Alpha Biopharma.
New Hire
Executive Move
New Hire
Executive Move
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HighTide Therapeutics
Sign Up For FreeTo access detailed company insights
HighTide Therapeutics, Inc. is focused on developing innovative therapeutic solutions for chronic metabolic diseases, particularly those related to cardiovascular-kidney-metabolic (CKM) conditions. Their lead candidate, HTD1801, targets diseases driven by insulin resistance and chronic inflammation. The company also has a growing discovery portfoli... Read More
